Medico-legal Services

Publications

Peer-reviewed publications

 

  1. Chadwick D, Jenner P, Reynolds EH. Amines, anticonvulsants and epilepsy. Lancet (1975) I:473-476.
  2. Asselman P, Chadwick D, Marsden CD. Visual evoked responses in the diagnosis and management of patients suspected of multiple sclerosis. Brain (1975) 98:26l-282.
  3. Reynolds, EH, Chadwick D, Jenner P, Chanarin I. Folate and monoamine metabolism in epilepsy. J. Neurol.Sci. (1975) 26:605-6l5.
  4. Jenner P, Chadwick D, Reynolds EH, Marsden CD. Altered 5HT metabolism with clonazepam, diazepam and diphenylhydantoin. J. Pharm.Pharmac. (1975) 27:707-7l0.
  5. Chadwick D, Harris R, Jenner P, Reynolds EH, Marsden CD. Manipulation of brain serotonin in the treatment of myoclonus. Lancet (1975) II:434-435.
  6. Reynolds EH, Chadwick D, Galbraith AW. One drug (Phenytoin) in the treatment of epilepsy. Lancet (l976) 1:923-926.
  7. Chadwick D, Reynolds EH, Marsden CD. Anticonvulsant induced dyskinesias: A comparison with dyskinesias induced by neuroleptics. J. Neurol.Neurosurg.Psychiat. (1976) 39:l2l0-l2l8.
  8. Chadwick D, Jenner P, Reynolds, EH. Serotonin metabolism in human epilepsy. Ann. Neurol. (1977) l:2l8-224.
  9. Chadwick D, Hallett M, Harris R, Jenner P, Reynolds EH, Marsden CD. Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and Clonazepam. Brain (1977) l00:455-487.
  10. Hallett M, Chadwick D, Marsden CD. Ballistic movement overflow myoclonus – A form of essential myoclonus. Brain (1977) l00:299-312.
  11. Hallett M, Chadwick D, Adam J, Marsden CD. Reticular reflex myoclonus: A physiological type of human post-hypoxic myoclonus. J. Neurol.Neurosurg.Psychiat. (1977) 40: 253-312.
  12. Elliott PNC, Jenner P, Chadwick D, Reynolds E, Marsden CD. The effect of diphenylhydantoin on central catecholamine containing neuronal systems. J.Pharm Pharmac (1977) 29-41.
  13. Chadwick D, Trimble M, Jenner P, Driver MV, Reynolds EH. Manipulation of Cerebral Monoamines in the Treatment of human epilepsy: A pilot study. Epilepsia (1978) l9:3-l1.
  14. Chadwick D, Hallett M, Jenner P, Marsden CD. 5-Hydroxytryptophan-induced myoclonus in guinea pigs. Journal of Neurological Sciences (1978) 35:l57-l65.
  15. Shorvon SD, Chadwick D, Galbraith AW, Reynolds EH. One drug for epilepsy. British Medical Journal (1978) l:474-476.
  16. Chadwick D, Gorrod JW, Jenner P, Marsden CD, Reynolds EH. Functional changes in cerebral 5-hydroxytryptamine metabolism in the mouse induced by anticonvulsant drugs. Br. J. Pharmac. (1978) 62:ll5-l24.
  17. Hallett M, Chadwick D, Marsden CD. Cortical reflex myoclonus. Neurology (1979) 29:ll07-ll25.
  18. Chadwick D, Cummings WJK, Livingstone I, Cartlidge NEF. Acute Intoxication with Sodium Valproate. Ann. Neurol (1979) 6:552-553.
  19. Chadwick D, Jenner P, Marsden CD. 5-Hydroxytrypamine and Myoclonus induced by l,2-Di-hydroxybenzene (Catechol) in the guinea-pig. Br. J. Pharmac. (1979) 66:358-360.
  20. Chadwick D, French AT. Uraemic myoclonus: An example of reticular reflex myoclonus? J. Neurol.Neurosurg.Psychiat. (1979) 42:52-55.
  21. Chadwick D, Hartley E, Mackinnon DM. Meningitis caused by candida tropicalis. Arch Neurol (1980) 37:175-176
  22. Chadwick D, Hallett M, Jenner P, Marsden CD. Observations on Chloralose-induced myoclonus in guinea-pigs. Br.J. Pharmac. (1980) 69:535-540
  23. Reynolds EH, Shorvon SD, Galbraith AW, Chadwick D, Dellaportas CI, Vydelingum L. Phenytoin Monotherapy for Epilepsy: A long-term prospective study, assisted by serum level monitoring,in previously untreated patients. Epilepsia (1981) 22:475-488.
  24. Turnbull DM, Rawlins MD, Weightman D, Chadwick DW. A comparison of phenytoin and valproate in previously untreated adult epileptic patients. J.Neurol.Neurosurg. Psychiat. (1982) 45:55-59.
  25. Chadwick D, Martin S, Buxton PH, Tomlinson AH. Measles virus and subacute neurological disease: an unusual presentation of measles inclusion body encephalitis. J. Neurol. Neurosurg. Psychiat. (1982)
  26. UK-TIA Study Group (Chadwick D – member). Variation inthe use of angiography and carotid endarterectomy by neurologists in the UK-TIA aspirin trial. B.M.J. (1983) 286:514-517.
  27. Turnbull DM, Rawlins MD, Weightman D, Chadwick DW. Plasma concentrations of sodium valproate: their clinical value. Ann. Neurol. (1983) 14:38-42.
  28. Shaw MDM, Foy P, Chadwick D. The effectiveness of prophylactic anticonvulsants following neurosurgery. Acta Neurochirugica (1983) 69:253-258.
  29. Marcus SN, Chadwick D, Walker RJ. D-penicillamine-induced myasthenia gravis in primary biliary cirrhosis. Gastroenterology (1984) 86:166-168.
  30. Turnbull, D.M., Rawlins, M.D., Weightman, D., Chadwick, D.W. “Therapeutic” serum concentration of phenytoin: the influence of seizure type. J. Neurol. Neurosurg & Psychiat. 1984;47:231-234.
  31. Greenwood RJ, Hughes RAC, Bowden AN, Gordon NS, Millac P, Newsom-Davies J, Aslan S, Chadwick D, McClellan DL, Stott RB, Armitage P. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet (1984) 1:877-879.
  32. Chadwick D, Shaw MDM, Foy P, Rawlins MD, Turnbull DM. Serum anticonvulsant concentrations and the risk of drug-induced skin eruptions. J. Neurol. Neurosurg. Psychiat. (1984) 47:642-644.
  33. Turnbull DM, Howel D, Rawlins MD, Chadwick D. Which drug for the adult epileptic patient: phenytoin or valproate? British Medical Journal 1985;290:815-819.
  34. Chadwick D, Turnbull DM. The comparative efficacy of antiepileptic drugs for partial and tonic-clonic seizures. Journal of Neurology, Neurosurgery and Psychiatry 1985;48:1073-1077
  35. Shaw MDM, Foy PM, Conway M, Pickard JD, Maloney P, Spillane JA, Chadwick D. Dipyridamole and postoperative ischaemic deficits in aneurysmal subarachnoid haemorrhage. J. Neurosurg. 1985;63:699-703.
  36. O’Driscoll K, Ghadiahli E, Crawford P, Chadwick D. A comparison of single dose and divided dose of phenytoin in epileptic out-patients. Acta Therapeutica 1985;11:375-385.
  37. Crawford PM, West CR, Chadwick DW, Shaw MDM. Arteriovenous malformations of the brain: natural history in unoperated patients. J. Neurol. Neurosurg. Psychiat. 1986;49:1-10.
  38. Crawford PM, Chadwick D, Cleland P, Tjia J, Cowie A, Black DJ, Orme M L’E. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. Contraception 1986;33:23-29.
  39. Crawford PM, West CR, Shaw MDM, Chadwick DW. Cerebral arteriovenous malformations and epilepsy: Factors in the development of epilepsy. Epilepsia 1986;27:270-275.
  40. Wroe SJ, Foy PM, Shaw MDM, Williams IR, Chadwick DW, West C, Towns G. Differences between neurological and neurosurgical approaches in the management of malignant brain tumours. British Medical Journal 1986;293:1015-1018.
  41. Crawford PM, Chadwick D. A comparative study of progabide, valproate and placebo as add-on therapy in patients with refractory epilepsy. Journal of Neurology, Neurosurgery and Psychiatry 1986;49:1251-1257.
  42. Crawford P, Ghadiali E, Lane R, Blumhardt L, Chadwick D. Gabapentin as an antiepileptic drug in man. Journal of Neurology, Neurosurgery & Psychiatry 1987;50:682-686.
  43. Crawford PM, Chadwick DW. GABA and amino acid concentrations in lumbar CSF in patients with treated and untreated epilepsy. Epilepsy Res. 1987;1:328-338.
  44. O’Neill P, West CR, Chadwick DW, Conway M, Foy PM, Maloney P, Pickard J, Spillane JA, Shaw MDM. Recurrent aneurysmal subarachnoid haemorrhage : incidence, timing and effects. A reappraisal in a surgical series. British Journal of Neurosurgery 1988;2:43-48.
  45. O’Neill P, West CR, Chadwick DW, Conway M, Foy PM, Maloney P, Pickard J, Spillane JA, Shaw MDM. Post-ictal blood pressure in aneurysmal subarachnoid haemorrhage. British Journal of Neurosurgery 1988;2:153-160.
  46. Crawford PM, LLoyd KG, Chadwick D. CSF gradients for aminoacid neurotransmitters. Journal of Neurology, Neurosurgery & Psychiatry 1988;51:1193-1200.
  47. Crawford PM, Belchetz P, Davis C, Chadwick D. Growth hormone response to diazepam, clonidine and glucagon in patients with epilepsy. Epilepsy Res1989;3:63-69.
  48. Howell SJL, Owen L, Chadwick D. Pseudostatus epilepticus. Quarterly Journal of Medicine 1989;71(266):507-519.
  49. UK Gabapentin Study Group. (D. Chadwick – Clinical Co-ordinator). Gabapentin in partial epilepsy. Lancet 1990;335:1114-1117.
  50. Sandeman DR, Sandeman AS, Buxton P, Hughes HH, Chadwick DW, Williams IR, Baker RD, Foy PM, Shaw MDM. The management of patients with an intrinsic supratentorial brain tumour. British Journal of Neurosurgery 1990;4:299-312.
  51. Crawford P, Chadwick D, Martin C, Tija J, Back DJ, Orme M. Oral contraceptives and antiepileptic drugs. British Journal of clincal Pharmacology, 1990;30:892-896.
  52. Baker GA, Smith DF, Dewey M, Morrow J, Crawford P, Chadwick D. The development of a seizure severity scale as an outcome measure in epilepsy. Epilepsy Research 1991;8:245-251.
  53. Medical Research Council Antiepileptic Drug Withdrawal Study Group. (D Chadwick, Clinical Co-ordinator) Randomised study of antiepileptic drug withdrawal in patients in remission. Lancet 1991;337:1175-1180.
  54. Young CA, Chadwick D, Humphrey PDR. Extracranial vertebral artery dissection following tonic-clonic seizure. Journal of Neurology Neurosurgery & Psychiatry 1991;54:365-366.
  55. European Carotid Surgery Trialists Collaborative Group. (Chadwick D – Member). European carotid surgery trial: Interim results for symptomatic patients with severe (70-99%) or mild (0- 29%) stenosis. Lancet 1991;337:1235-43.
  56. Smith DF, Hutton JL, Sandeman D, Foy PM, Shaw MDM, Williams IR, Chadwick D. The prognosis of primary intracerebral tumours presenting with epilepsy: the outcome of medical and surgical mangement. Journal of Neurology, Neurosurgery & Psychiatry 1991;54:915-920.
  57. Smith DF, Baker GA, Dewey M, Jacoby A, Chadwick D. Seizure frequency, patient perceived seizure severity and the psychosocial consequences of intractable epilepsy. Epilepsy Research 1991;9:231-241.
  58. Pirmohamed M, Graham A, Roberts P, Smith D, Chadwick D, Breckenridge AM, Park BK. Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. British Journal of Clinical Pharmacology 1991;32:741-749.
  59. UK-TIA Study Group (D Chadwick – member). The United Kingdom transient ischaemic attack aspirin trial: final results. Journal of Neurology Neurosurgery and Psychiatry 1991;54:1044-1054.
  60. Hutton JL, Smith DF, Sandemann D, Foy PM, Shaw MDM, Williams IR, Chadwick DW. Development of a prognostic index for primary supratentorial intracerebral tumours. Journal of Neurology, Neurosurgery & Psychiatry 1991;55:271-274.
  61. Jacoby A, Johnson A, and Chadwick D. Psychosocial outcomes of antiepileptic drug discontinuation. Epilepsia 1992;33:1123-1131.
  62. Foy PM, Chadwick DW, Rajgopalan N, Johnson AL, Shaw MD. Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy? J Neurol Neurosurg Psychiatry. 1992 Sep;55(9):753-7.
  63. Smith D, Baker G, Davies G, Dewey M, Chadwick D. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:312-322.
  64. Medical Research Council Antiepileptic Drug Withdrawal Study Group. (D. Chadwick, Clinical Co-ordinator) Prognostic index for recurrence of seizures after remission of epilepsy. British Medical Journal. 1993;306:1374-1378.
  65. Jacoby Ann, Baker G, Smith D, Dewey M, Chadwick D. Measuring the impact of epilepsy: the development of a novel scale. Epilepsy Research 1993;16:83-88.
  66. Baker GA, Smith DF, Dewey M, Jacoby A and Chadwick D. The initial development of a health-related quality of life model as an outcome measure in epilepsy. Epilepsy Research 1993;16:65-81.
  67. Jacoby A, Baker G, Chadwick D, Johnson A. The impact of counselling with a practical statistical model on patients’ decision-making about treatment for epilepsy: findings from a pilot study. Epilepsy Research 1993;16:207-214.
  68. Moore PM, Baker GA, McDade, Chadwick D, Brown S. Epilepsy, pseudoseizures and perceived family characteristics: a controlled study. Epilepsy Research 1994;18:75-83.
  69. Pirmohamed M, Allott R, Green VJ, Kitteringham NR, Chadwick D and Park BK. Lymphocyte microsomal epoxide hydrolase in patients on carbamazepine therapy. Br J Clin Pharmac 1994;37:577-581.
  70. Heller AJ, Chesterman P, Elwes RDC, Crawford P, Chadwick D, Johnson AL, Reynolds EH. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. JNNP 1995;58:44-50.
  71. Taylor J, Chadwick D, Johnson T. Accident experience and notification rates in people with recent seizures, epilepsy or undiagnosed episodes of loss of consciousness. Q.J. Med. 1995; 88:733-740.
  72. Richens A, Chadwick D, Duncan J.S, Dam M, Gram L, Mikkelsen M, Morrow J, Mengel H, Shu V, McKelvy J.F, Pierce M.W. Adjunctive treatment of partial seizures with Tiagabine: A placebo-controlled trial. Epilepsy Research 21 (1995) 37-42
  73. Wagner AK, Keller SD, Kosinski M, Baker GA, Jacoby A, Husu M-A, Chadwick DW, Ware JE. Advances in methods for assessing the impact of epilepsy and antiepileptic drug therapy okn patients’ health-related quality of life. Qulity of Life Research 1995;4:115-134.
  74. Jacoby A, Baker GA, Steen N, Potts P, Chadwick DW. The clinical course of epilepsy and its psychosocial correlates: Findings from a UK Community Study. Epilepsia 1996;37:148-161.
  75. Baker GA, Jacoby A, Chadwick DW. The associations of psychopathology in epilepsy: a community study. Epilepsy Research 1996;25:29-39
  76. Marson AG, Chadwick DW. How easy are randomized controlled trials in epilepsy to find on Medline?: The sensitivity and precision of two Medline searches. Epilepsia 1996;37(4):377-380.
  77. Taylor J, Chadwick D, Johnson T. Risk of accidents in drivers with epilepsy. Journal of Neurology, Neurosurgery & Psychiatry 1996;60:621-627.
  78. Elmslie FV, Williamson MP, Rees M, Kerr M, Kjeldsen MJ, Pang KA, Sundqvist A, Friis ML, Richens A, Chadwick D, Whitehouse WP, Gardiner RM. Linkage analysis of juvenile myoclonic epilepsy and microsatellite loci-spanning 61 cM of human chromosome 6p in 19 nuclear pedigrees provides no evidence for a susceptibility locus in this region. Am. J. Hum. Genet. 1996;59:653-663.
  79. Jacoby A, Graham-Jones S, Baker G, Ratoff L, Heyes J, Dewey M, Chadwick D. A general practice records audit of the process of care for people with epilepsy. Br. J. Gen. Prac. 1996;46:595-599.
  80. Schapel G and Chadwick D. A survey comparing lamotrigine and vigabatrin in everyday clinical practice. Seizure 1996;5:267-270.
  81. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996;313:1169-1174.
  82. Chadwick D, Taylor J, Johnson T on behalf of the MRC Antiepileptic Drug Withdrawal Group. Outcomes after seizure recurrence in people with well-controlled epilepsy and the factors that influence it. Epilepsia 1996;11:1043-1050.
  83. Chadwick D, Leiderman D, Sauermann W, Alexander J, Garofalo E. Gabapentin in generalised seizures. Epilepsy Research 1996;25:191-197.
  84. Appleton RE, Chadwick D, Sweeney A. Managing the teenager with epilepsy: paediatric to adult care. Seizure 1997;6:27-30.
  85. Elmslie FV, Rees M, Williamson MP, Kerr M, Kjeldsen MJ, Pang K, Sundqvist A, Friis ML, Chadwick D, Richens A, Convanis A, Santos M, Arzimanoglou A, Panayiotopoulos CP, Curtis D, Whitehouse WP, Gardiner RM. Genetic mapping of a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q. Human Molecular Genetics 1997;6:1329-1334.
  86. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997;38(8):859-880.
  87. Buck D, Baker GA, Jacoby A, Chadwick D. Patients’ experiences of injury as a result of epilepsy. Epilepsia 1997;38(4):439-44.
  88. Buck D, Jacoby A, Baker GA, Chadwick D. Factors affecting patients’ compliance with antiepileptic drug therapy. Seizure 1997;6:87-93.
  89. Kellett M, Smith DF, Baker GA, Chadwick D. Quality of life after epilepsy surgery. JNNP 1997;63(1):52-58.
  90. Jacoby A, Buck D, Baker G, McNamee P, Graham-Jones S, Chadwick D. Uptake and costs of care for epilepsy: findings from a UK regional study. Epilepsia 1998;39(7):776-786.
  91. Cochrane HC, Marson AG, Baker, GA, Chadwick DW. Neuropsychological outcomes in randomised controlled trials of antiepileptic drugs: A systematic review of methodology and reporting standards. Epilepsia 1998;39(10):1088-1097.
  92. Kalviainen R, Brodie MJ, Duncan J, Chadwick D, Edwards D, Lyby K. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Northern European Tiagabine Study Group. Epilepsy Research 1998;30(1):31-40.
  93. Vickrey BG, Gifford DR, Belin TR, Martin PJ, Smith D, Delrahim S, Chadwick DW. Practice styles of US compared to UK neurologists. Neurology 1998;50(6):1661-1668.
  94. Chadwick DW, Anhut H, Greiner MJ, Alexander MS, Murray GH, Garofalo EA, Pierce MW, International Gabapentin Monotherapy Study Group. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology 1998;51:1282-1288.
  95. Smith D, Defalla BA, Chadwick DW. The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. Quarterly Journal of Medicine 1999;92:15-23.
  96. Leach JP, Chadwick DW, Miles JB and Hart IK. Adult-onset Rasmussen’s encephalitis improvement with long-term immunomodulatory therapy. Neurology 1999;52(4):738-742.
  97. Webb JA, Guimond A, Eldridge P, Chadwick D, Meunier J, Thirion JP, and Roberts N. Automatic detection of hippocampal atrophy on magnetic resonance images. Magnetic Resonance Imaging 17, 1149-1161 (1999).
  98. Chadwick D. Does withdrawal of different antiepileptic drugs have different effects on seizure recurrence? Further results from the MRC Antiepileptic Drug Withdrawal Study. Brain 1999;122:441-8.
  99. Chadwick D (for the Vigabatrin European Monotherapy Study Group). Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet 1999;354:13-19.
  100. Wong IC, Chadwick DW, Fenwick PB, Mawer GE, Sander JW. The long-term use of gabapentin, lamotrigine and vigabatrin in patients with chronic epilepsy. Epilepsia 1999;40:1439-45.
  101. Kellett MW, Smith DF, Stockton PA, Chadwick DW. Topiramate in clinical practice: first year’s post-licensing experience in a specialist epilepsy clinic. Journal of Neurology, Neurosurgery & Psychiatry. 1999;66:759-63.
  102. Chadwick D, Clear DB, Eldridge P, Malucci C. Golf ball epilepsy. JNNP 2000;68:251-252.
  103. Clear D, Chadwick DW. Seizures provoked by blows to the head. Epilepsia 2000;41:243-4.
  104. Chadwick D, Marson AG. Zonisamide for drug-resistant partial epilepsy. Cochrane Database of Syst. Rev. 2000(2):CD001416.
  105. Marson AG, Kadir ZA, Hutton JL, Chadwick D. Gabapentin for drug-resistant partial epilepsy. Cochrane Database of Syst. Rev. 2000(2):CD001415.
  106. Aldenkamp AP, Baker G, Mulder OG, Chadwick D, Cooper P, Doelman J, Duncan R, Gassmann-Mayer C, de Haan GJ, Hughson C, Hulsman J, Overweg J, Pledger G, Rentmeester TW, Riaz H, Wroe S. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000;41(9):1167-1178.
  107. Williamson PW, Marson AG, Tudor C. Hutton JL, Chadwick D. Individual patient data meta-analysis of randomised antiepileptic drug monotherapy trials. J Eval Clin Pract. 2000 May;6(2):205-14.
  108. Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy (Cochrane review). Cochrane Database Syst Rev. 2000;(3):CD001030.
  109. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. Gabapentin add-on for drug-resistant partial epilepsy (Cochrane review). Cochrane Database Syst Rev. 2000;(3):CD001415.
  110. Silverdale M, Leach JP, Chadwick DW. New variant Creutzfeldt-Jakob disease presenting as localisation-related epilepsy. Neurology 2000 Jun 13;54(11):2188.
  111. Mackay CE, Webb JA, Eldridge PR, Chadwick DW, Whitehouse GH, Roberts N. Quantitative magnetic resonance imaging in consecutive patients evaluated for surgical treatment of temporal lobe epilepsy. Magn Reson Imaging. 2000 Dec;18(10):1187-99
  112. Chadwick D, Smith D, Crawford P, Harrison B. Remacemide hydrochloride: a placebo-controlled, one month, double-blind assessment of its safety, tolerability and pharmacokinetics as adjunctive therapy in patients with epilepsy. Seizure 2000 Dec;9(8):544-50.
  113. Marson AG, Chadwick DW. New drug treatment for epilepsy. J Neurol Neurosurg Psychiatry. 2001 Feb:70(2):143-7.
  114. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK. Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol. 2001 Apr;51(4):345-349.
  115. Pirmohamed M, Lin K, Chadwick D, Park BK. TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 2001 Apr 10;56(7):890-6.
  116. Chappell AS, Sander JW, Brodie MJ, Chadwick D, Lledo A, Zhang D, Bjerke J, Kiesler GM, Arroyo S. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 2002; 58 (June ):1680-1682.
  117. Brodie MJ, Chadwick DW, Anhut H, Otte A, Messmer S-L, Maton S, Sauermann W, Murray G, Garofalo EA for the Gabapentin Study Group 945-212. Gabapentin versus Lamotrigine Monotherapy: A Double-blind Comparison in Newly Diagnosed Epilepsy. Epilepsia 2002;43(9):993-1000.
  118. Williamson PR, Clough HE, Hutton JL, Marson AG, Chadwick DW. Statistical issues in the assessment of the evidence for an interaction between factors in epilepsy trials. Stat Med 2002 Sep 30;21(18):2613-22.
  119. Nicolson A, Leach JP, Chadwick DW, Smith DF. The legacy of vigabatrin in a regional epilepsy clinic. J Neurol Neurosurg Psychiatry 2002 Sep;73(3):327-9.
  120. Taske NL, Williamson MP, Makoff A, Bate L, Curtis D, Kerr M, Kjeldsen MJ, Pang KA, Sundqvist A, Friis ML, Chadwick D, Richens A, Covanis A, Santos M, Arzimanoglou A, Panayiotopoulos CP, Whitehouse WP, Rees M, Gardiner RM. Evaluation of the positional candidate gene CHRNA7 at the juvenile myoclonic epilepsy locus (EJM2) on chromosome 15q13-14. Epilepsy Res 2002 Apr;49(2)157-72.
  121. Marson AG, Williamson PR, Clough H, Hutton JL, Chadwick DW; Epilepsy Monotherapy Trial Group. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia. 2002;43(5):505-13.
  122. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S, for the EPMN 105 Study Group. Topiramate, Carbamazepine and Valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003;107:165-175.
  123. Doose DR, Brodie MJ, Wilson EA, Chadwick D, Oxbury J, Berry DJ, Schwabe S, Bialer M. Topiramate and Lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Epilepsia 2003 Jul;44(7):917-22.
  124. Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, Gibney CA, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK. Characterisation of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol. 2003 Jun;111(6):1393-403.
  125. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, Pichler WJ, Primohamed M, Park BK. Hypersensitivity reactions to carbamazepine: characterisation of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmcol 2003 Mar;63(3):732-41.
  126. Wieshmann UC, Denby CE, Eldridge PR, Roberts N, Mackay CE, Webb JA, Tedman BM, Chadwick DW, Smith DF. Foramen ovale recordings: a presurgical investigation in epilepsy. Eur Neurol 2003;49(1):3-7.
  127. Beghi E, Gatti G, Tonini C, Ben-Menachem E, Chadwick DW, Nikanorova M, Gromov SA, Smith PE, Specchio LM, Perucca E. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res. 2003 Nov;57(1):1-13
  128. Nicolson A, Appleton RE, Chadwick DW, Smith DF. The relationship between treatment with valproate, lamotrigine, and Topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):75-9.
  129. Nicolson A, Chadwick DW, Smith DF. A comparison of adult onset and “classical” idiopathic generalised epilepsy. J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):72-4.
  130. Nicolson A, Chadwick DW, Smith DF. The coexistence of idiopathic generalized epilepsy and partial epilepsy. Epilepsia. 2004 Jun;45(6):682-5.
  131. Reuber M, Baker GA, Gill R, Smith DF, Chadwick DW. Failure to recognize psychogenic nonepileptic seizures may cause death. Neurology. 2004 Mar 9;62(5):834-5.
  132. McCorry DJ, Chadwick DW, Barber P, Cooper PM, Wroe S. Cough syncope in Heavy Goods Vehicle drivers. QJM. 2004 Sep;97(9):631-2.
  133. Gaitatzis A, Johnson AL, Chadwick DW, Shorvon SD, Sander JW. Life expectancy in people with newly diagnosed epilepsy. Brain. 2004 Nov;127(11):2427-32.
  134. Adab N, Kini U, Vinten J, Ayres J, Baker G, Clayton-Smith J, Coyle H, Fryer A, Gorry J, Gregg J, Mawer G, Nicolaides P, Pickering L, Tunnicliffe L, Chadwick DW. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2004 Nov;75(11):1575-83.
  135. Chadwick D, Marson A, Chadwick D. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD001416.
  136. Hawkins N, Epstein D, Drummond M, Wilby J, Kainth A, Chadwick D, Sculpher M. Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model. Med Decis Making. 2005 Sep-Oct;25(5):493-510
  137. Marson A, Jacoby A, Johnson A, Kim L, Gamble C, Chadwick D. Medical Research Council MESS Study Group. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet. 2005 Jun 11-17;365(9476):2007-13.
  138. Hawkins N, Epstein D, Drummond M, Wilby J, Kainth A, Chadwick D, Sculpher M. Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults:the results of a probabilistic decision model. Med Decis Making. 2005 Sep-Oct;25(5):493-510.
  139. Owen A, Goldring C, Morgan P, Chadwick D, Park BK, Pirmohamed M. Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol. 2005 Mar;59(3):365-70.
  140. McCorry D, Nicolson A, Smith D, Marson A, Feltbower RG, Chadwick DW. An association between type 1 diabetes and idiopathic generalized epilepsy.Ann Neurol. 2006 Jan;59(1):204-6.
  141. Alfirevic A, Mills T, Harrington P, Pinel T, Sherwood J, Jawaid A, Smith JC,March RE, Barratt BJ, Chadwick DW, Kevin Park B, Pirmohamed M. Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet Genomics. 2006 Apr;16(4):287-96.
  142. Kim LG, Johnson TL, Marson AG, Chadwick DW; MRC MESS Study group. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol. 2006 Apr;5(4):317-22.
  143. Gamble C, Williamson PR, Chadwick DW, Marson AG. A meta-analysis of individual patient responses to lamotrigine or carbamazepine monotherapy. Neurology. 2006 May 9;66(9):1310-7.
  144. Fowler HL, Baker GA, Tipples J, Hare DJ, Keller S, Chadwick DW, Young AW. Recognition of emotion with temporal lobe epilepsy and asymmetrical amygdale damage. Epilepsy Behav. 2006 Jun 8; 164-72
  145. Leschziner G, Jorgensen AL, Andrew T, Pirmohamed M, Williamson PR, Marson AG, Coffey AJ, Middleditch C, Rogers J, Bentley DR, Chadwick DW, Balding DJ, Johnson MR. Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. Lancet Neurol. 2006 Aug;5(8):668-76.
  146. Marson AG, Williamson PR, Taylor S, Maguire M, Chadwick DW. Efficacy of carbamazepine and valproate as monotherapy for early epilepsy and single seizures. Neurology. 2006 Nov 28;67(10):1872-5.
  147. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR; SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.Lancet. 2007 Mar 24;369(9566):1000-15.
  148. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR; SANAD Study group. The SANAD study of effectiveness of valroate, lamotrigine, or topiramate for treatment of generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007 Mar 24;369(9566):1016-26.
  149. Jacoby A, Gamble C, Doughty J, Marson A, Chadwick D; Medical Research Council MESS Study Group. Quality of life outcomes of immediate or delayed treatment of early epilepsy and single seizures. Neurology. 2007 Apr 10;68(15):1188-96.
  150. Leschziner GD, Andrew T, Leach JP, Chadwick D, Coffey AJ, Balding DJ, Bentley DR, Pirmohamed M, Johnson MR. Common ABCB1 polymorphisms are not associated with multidrug resistance in epilepsy using a gene-wide tagging approach. Pharmacogenet Genomics. 2007 Mar;17(3):217-20.
  151. Leschziner GD, Jorgensen AL, Andrew T, Williamson PR, Marson AG, Coffey AJ,Middleditch C, Balding DJ, Rogers J, Bentley DR, Chadwick D, Johnson MR,Pirmohamed M. The association between polymorphisms in RLIP76 and drug response in epilepsy. Pharmacogenomics. 2007 Dec;8(12):1715-1722.
  152. Marson AG, Appleton R, Baker GA, Chadwick DW, Doughty J, Eaton B, Gamble C, Jacoby A, Shackley P, Smith DF, Tudur-Smith C, Vanoli A, Williamson PR. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technol Assess. 2007 Oct;11(37):iii-iv, ix-x, 1-134.
  153. Quenby SM, Anin S, Bates MD, Chadwick D, Vince GS, Neilson JP. Phenytoin but not valproate directly affected in vitro trophoblast differentiation.Eur J Obstet Gynecol Reprod Biol. 2008 Mar;137(1):31-6. Epub 2007 May 31.
  154. Tudur Smith C, Marson AG, Chadwick DW, Williamson1 PR. Multiple treatment comparisons in epilepsy monotherapy trials. Trials. 2007 Nov 5;8(1):34.
  155. Lozsadi DA, Chadwick DW, Larner AJ. Late-onset temporal lobe epilepsy with unilateral mesial temporal sclerosis and cognitive decline: A diagnostic dilemma. Seizure. 2008 Jul;17(5):473-6. Epub 2008 Jan 31.
  156. Chadwick D, Jelen P, Almond S. Life and death diagnosis. Pract Neurol. 2010 Jun;10(3):155-9. PubMed PMID: 20498188.
  157. Mawer G, Briggs M, Baker GA, Bromley R, Coyle H, Eatock J, Kerr L, Kini U, Kuzmyshcheva L, Lucas SB, Wyatt L, Clayton-Smith J; Liverpool & Manchester Neurodevelopment Group. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure. 2010 Mar;19(2):112-9. Epub 2009 Dec 24.
  158. Chadwick D. NICE and neurology. Pract Neurol. 2009 Oct;9(5):278-83.
  159. Meador KJ, Penovich P, Baker GA, Pennell PB, Bromfield E, Pack A, Liporace JD,Sam M, Kalayjian LA, Thurman DJ, Moore E, Loring DW; NEAD Study Group.Antiepileptic drug use in women of childbearing age. Epilepsy Behav. 2009 Jul;15(3):339-43. Epub 2009 May 27
  160. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW; NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009 Apr 16;360(16):1597-605.
  161. Chadwick D, Shukralla A, Marson T. Comparing drug treatments in epilepsy. Ther Adv Neurol Disord. 2009 May;2(3):181-7.
  162. Chadwick D. NICE and neurology. Pract Neurol. 2009 Oct;9(5):278-83.
  163. Mawer G, Briggs M, Baker GA, Bromley R, Coyle H, Eatock J, Kerr L, Kini U, Kuzmyshcheva L, Lucas SB, Wyatt L, Clayton-Smith J; Liverpool & Manchester Neurodevelopment Group. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure. 2010 Mar;19(2):112-9.
  164. Chadwick D, Jelen P, Almond S. Life and death diagnosis. Pract Neurol. 2010 Jun;10(3):155-9.
  165. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW; NEAD Study Group. Effects of breastfeeding in children of women taking antiepileptic drugs. Neurology. 2010 Nov 30;75(22):1954-60. doi: 10.1212
  166. Meador KJ, Baker GA, Browning N, Cohen MJ, Clayton-Smith J, Kalayjian LA,Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW; NEAD Study Group. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain. 2011 Feb;134(Pt 2):396-404. doi: 10.1093/brain/awq352.
  167. Chadwick D. Random events. Pract Neurol. 2011 Apr;11(2):111-2. doi:10.1136/jnnp.2011.241570.
  168. Bonnett L, Smith CT, Smith D, Williamson P, Chadwick D, Marson AG. Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial. Lancet Neurol. 2012 Apr;11(4):331-40. doi: 10.1016/S1474-4422(12)70018-2.
  169. Javed S, Safdar A, Forster A, Selvan A, Chadwick D, Nicholson A, Jacob A. Refractory coeliac disease associated with late onset epilepsy, ataxia, tremor and progressive myoclonus with giant cortical evoked potentials–a case report and review of literature. Seizure. 2012 Jul;21(6):482-5. doi:10.1016/j.seizure.2012.04.003.
  170. Bonnett L, Smith CT, Smith D, Williamson P, Chadwick D, Marson AG. Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial. Lancet Neurol. 2012 Apr;11(4):331-40.
  171. IST-3 collaborative group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012 Jun 23;379(9834):2352-63. doi: 10.1016/S0140-6736(12)60768-5. (D Chadwick, Chairman, Trial Steering Group)
  172. Rogers JK, Hutton J, Marson AG, Chadwick DW. Assessing the risk of subsequent tonic-clonic seizures in patients with a history of simple or complex partial seizures. J Neurol Neurosurg Psychiatry. 2012 Aug;83(8):803-9. doi: 10.1136/jnnp-2011-300917.
Back to Top